by barry-jtcir | Mar 18, 2025 | Press Releases
Access the CEO Connect segment here LA JOLLA, CA, March 18, 2025 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators...
by barry-jtcir | Mar 17, 2025 | Press Releases
Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively Cash runway expected to fund operations into Q2 2025, including interim data readout from GRI-0621 LA JOLLA, CA, March 17, 2025 — GRI Bio, Inc....
by barry-jtcir | Mar 11, 2025 | Press Releases
LA JOLLA, CA, March 11, 2025 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory,...
by barry-jtcir | Feb 19, 2025 | Press Releases
GRI’s common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025 LA JOLLA, CA, Feb. 19, 2025 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
by barry-jtcir | Feb 19, 2025 | Press Releases
On-demand video webcast now available here LA JOLLA, CA, Feb. 19, 2025 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
by barry-jtcir | Dec 23, 2024 | Press Releases
– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators LA JOLLA, CA, Dec. 23, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
